News
Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your ...
While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...
The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...
The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...
The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...
Blue Cross plans are retreating from GLP-1 weight-loss drug coverage after spending hundreds of millions of dollars on the ...
A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s obesity drug Zepbound lost nearly 50% more weight than those using rival Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results